To determine the cost-effectiveness of management strategies for dysuria in different office settings.
A cute dysuria accounts for over 7 million office visits annually in the United States 1 at an aggregate cost exceeding 1 billion dollars. 2 Although numerous recommendations and clinical guidelines for dysuria have been available for as long as 25 years, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] no consensus has emerged. Researchers have questioned both the need for and the cost-effectiveness of any testing beyond empiric antibiotics, 3 including routine urine culture, 4,15 urinalysis, 11, 15, 19 and cultures for sexually transmitted disease. 20 Reflecting this disagreement, 137 family physicians responded to a clinical vignette with 82 distinct management strategies. 20 Part of this variation may be attributable to local disease prevalence, 21 antibiotic resistance, 1 or patient preferences, 22 factors not addressed in previous decision analyses. 3, 4 To examine various strategies for the evaluation and management of dysuria, we performed a cost-effectiveness analysis from the payer's perspective incorporating these potential sources of variation.
METHODS

Decision Model
We constructed a recursive decision tree using a standard computer program (Decision Maker 7.06, Pratt Medical Group, Boston, Mass), 23, 24 that analyzed the expected outcomes of 28 office-based strategies. The study population consisted of a hypothetical cohort of healthy women less than 65 years old presenting to the office with fewer than 7 days of dysuria accompanied by urgency or frequency, but without vaginal discharge, fever, flank pain, nausea, or vomiting. Pregnant women and those with diabetes, immunosuppression, or history of urinary tract abnormalities were excluded. Because patients with dysuria seek medical attention primarily to alleviate symptoms, we determined the average number of symptom-days associated with each strategy.
Diagnosis and Treatment.
We considered all logical combinations of urinalysis, pelvic exam/wet mount, urine culture, chlamydia/gonorrhea (sexually transmitted disease, STD) cultures, and empiric antibiotics for cystitis. Each test, as well as empiric treatment, could be applied routinely to all patients, selectively based on urinalysis results, or not at all, producing 28 reasonable strategies. Patients diagnosed with cystitis or treated empirically received 3 days of trimethoprim-sulfamethoxazole (tmp-smx). Although some experts now recommend quinolones as first-line therapy for uncomplicated cystitis due to concerns about resistance, 25 others continue to recommend tmp-smx to prevent emerging resistance to quinolones. 26, 27 Patients diagnosed with gonorrhea, chlamydia, vaginitis, or herpes on the basis of pelvic exam or culture were treated accordingly. 25 Further Evaluation. Patients were followed at 2-day intervals for up to 6 days. If symptoms improved, the patient was considered cured. Otherwise, the patient returned for a second office visit including pelvic exam, urinalysis, and urine culture. , as did we. In 2,068 patients in 10 treatment studies, 11,34,36 -43 the average prevalence of bacterial infection was 67% (range 46% to 78%). This formed our base case assumption. For patients without bacterial infection, our base case assumed a weighted average of surveys from 3 primary care sites 11, 39, 44 (Table 2 ) to estimate the prevalence of chlamydia, vaginitis, herpes, and gonorrhea. In additional analyses, we determined the optimal management strategy for each site, including a family practice site 45 with more lenient study entry criteria, by evaluating the model using disease prevalence from each site.
Data and Estimates
Test Characteristics. Most published estimates of the sensitivity and specificity of urinalysis for cystitis include hospitalized patient specimens. To avoid this documented spectrum bias, 46 we determined the sensitivity of urinalysis from studies limited to symptomatic ambulatory women. 62 A recent multicenter trial found that tmp-smx effectively eradicates half of resistant organisms. 63 Efficacy of antibiotics for patients with urethral syndrome, including "low-count" bacteriuria, was based on treatment trials and studies of the urethral syndrome. 15, 29, 34, 36, [38] [39] [40] 44, [64] [65] [66] [67] Finally, we assumed that women with nonbacterial urethritis and vaginitis would not respond to antibiotics.
Natural History. Combining data from the placebo arms of 2 treatment trials, 28, 68 we estimated the 2-day placebo cure rates to be 5% for cystitis and 35% for urethral syndrome. 64, 65 Other diseases (e.g., chlamydia) were assumed not to improve without treatment. 71 with death in 10% of cases.
For comparison purposes, we converted all outcomes into days of dysuria. Minor side effects lasted 3 days (the prescribed course), and were equal to the discomfort of dysuria, while serious side effects lasted 2.8 days (equal to the duration of inpatient pyelonephritis), and were 10 times worse than dysuria (i.e., 1 day of Stevens-Johnson syndrome equaled 10 days of dysuria). Death equaled a lifetime of dysuria. Although unconventional, converting death into days of dysuria is actually the inverse of traditional cost-effectiveness analysis, which assumes that both death and dysuria shorten quality-adjusted life expectancy. We assumed that both entities lengthen symptom-days, a metric more comprehensible to clinicians. More importantly, we tested all these relative values in sensitivity analysis.
Treatment trials suggest a 1% incidence of pyelonephritis due to stones or structural abnormalities. 30, 52, 53, 56 Patients who were not receiving effective antibiotics had an additional 2.5% risk of pyelonephritis every 2 days. 68, 72 Costs. All costs were in 2002 dollars and took the perspective of a medical payer. We included direct medical costs to the patient or insurer and excluded indirect costs such as time lost from work. Drug costs reflected the average wholesale price. We used the Medicare fee schedule 73 to determine costs for ambulatory visits and testing. Costs of pyelonephritis or serious side effects of medication were based on diagnosis related group fees for hospitalization. 74 
Sensitivity Analysis
Our base case consisted of the best estimate for each variable and etiology of disease as described above. In addition, we ran one-way sensitivity analysis on each variable through the ranges listed in Table 1 , with the exception of cost and prevalence of disease. We performed two-way sensitivity analysis by running each one-way analysis against the published prevalence of disease from 4 actual sites (Table 2) .
RESULTS
Base Case Analysis
The costs and benefits of many strategies were nearly identical. Table 3 lists all 28 strategies, which fall into 3 main groups from least to most expensive: 1) empiric antibiotics for cystitis, 2) testing based on urinalysis results, and 3) testing for all patients without urinalysis. Empiric antibiotic therapy was least effective and least expensive. The most effective strategies utilized one or more tests without urinalysis. These strategies were also the most expensive. Testing and treatment strategies based on urinalysis results were intermediate in both cost and effectiveness.
For women with pyuria or bacteriuria who failed therapy with tmp-smx, immediate retreatment with a quinolone 
Cost-effectiveness Analysis
The last column of Table 3 summarizes the results. Empiric antibiotics, the least expensive strategy, cost $90.92 per episode. Of the remaining strategies, 3 urinalysis strategies and 2 nonurinalysis strategies dominated all other strategies. These strategies all included empiric antibiotics with tmp-smx for undiagnosed patients at the end of the initial visit.
All 3 urinalysis strategies began with pelvic exam and urine culture for patients with normal urinalyses. Compared to empiric antibiotics alone, this basic strategy had a marginal cost of $4 per symptom-day avoided (SDA). Adding urine culture for patients with pyuria had a marginal cost of $64 per SDA. Including STD cultures at the pelvic examination had a marginal cost of $126 per SDA. Strategies without urinalysis were less cost-effective. Performing pelvic examination and STD cultures on all patients had a marginal cost of $185 per SDA. The most comprehensive approach-pelvic exam, STD cultures, and urine cultureproduced the fewest symptom-days, but the marginal costeffectiveness was $411 per SDA.
Sensitivity Analyses
We used sensitivity analysis to examine the potential effects of local variables on the cost-effectiveness of the different strategies.
Probability of Cystitis.
We varied the probability of cystitis over the range of values observed in 10 separate antibiotic treatment trials. A recent review article suggested that women with dysuria, frequency, and hematuria have an 81% probability of cystitis. 19 As the probability of cystitis increases, the benefit of empiric therapy also increases, while the cost declines. Figure 1 shows the effect of the probability of cystitis on the marginal cost-effectiveness of urinalysis and pelvic exam relative to empiric treatment with tmp-smx.
Etiology of Dysuria. We applied our model to 4 published populations, each with its own spectrum of disease, especially regarding prevalence of cystitis and vaginitis (Table 2) . Stamm 44 studied a university health service, which closely resembled our base case. Komoroff 11 found a higher rate of cystitis and a lower rate of vaginitis; Dans 39 found the opposite. In all 3 settings, cystitis was most prevalent, followed by urethral syndrome and then vaginitis. In contrast, among family practices, 45 vaginitis was twice as common as cystitis and half the patients had urethral syndrome.
The marginal cost-effectiveness ratios of the best strategies were similar in all 4 populations, despite the wide variation in the etiology of dysuria (Fig. 2) . Empiric antibiotic therapy was the least expensive strategy in all but Berg's population, where the probability of cystitis was low. Compared to empiric treatment alone, performing pelvic exam and urine culture for women with normal urinalyses varied from cost saving (Berg) to $32 per SDA (Komoroff ), depending on the proportion of patients with vaginitis.
The marginal cost-effectiveness of STD cultures or urine cultures for patients with pyuria varied widely from one population to the next, but always cost more than $50 per SDA in all populations. Performing pelvic exams on all patients without regard to urinalysis cost at least $185 per SDA, often much more. Only in Berg's population, with its low incidence of cystitis, was any nonurinalysis strategy potentially cost-effective.
Antibiotic Resistance. A patient may fail empiric antibiotic therapy either because of misdiagnosis or antibiotic resistance. In the latter case, an initial culture result confirms the diagnosis, allowing immediate treatment with another antibiotic, and obviating the need for further diagnostic testing. When resistance is low, however, few patients fail therapy, so few benefit from culture, although all incur the cost. Consequently, urine culture for patients with pyuria was not generally recommended. When resistance to tmpsmx increased, however, the percentage of patients failing empiric therapy increased, and more benefited from urine culture. When in vivo resistance reached 30%, the costeffectiveness of routine urine culture, compared to urine culture for negative urinalysis only, fell to $49 per SDA.
This effect was tempered by our finding that for patients with pyuria who failed therapy with tmp-smx, it was best to immediately retreat with a quinolone, without waiting for a culture result. For strategies that did not include immediate retreatment, initial urine cultures for pyuria were much more cost-effective ($8 per SDA at 30% resistance). Adverse Effects. Because the best strategies all included empiric antibiotics for the majority of patients, the results were generally insensitive to the probability, duration, and utility of all medication side effects, including serious complications and death, and the mortality associated with each strategy was virtually identical. As the probability and severity of antibiotic side effects increased, the costeffectiveness of testing improved only modestly. Varying the probability of pyelonephritis also had no significant effect.
Aversion to Pelvic Examination. We assumed an average woman would be willing to endure an extra 30 minutes of dysuria to avoid a pelvic examination (i.e., she would not consent to a pelvic examination unless she thought it would shorten her illness by at least 30 minutes). The model simulated this aversion by adding 30 minutes of dysuria for each pelvic examination. When urinalysis was negative, varying this time from 0 to 6 hours did not affect the choice of strategy because most women without pyuria did not have cystitis and required pelvic exam for diagnosis. Delaying the exam only prolonged symptoms. In contrast, by taking antibiotics, women with pyuria often avoided an exam altogether. Even assuming a low level of aversion, the marginal cost-effectiveness of performing pelvic examination without regard to urinalysis result exceeded $170 per SDA.
Sulfa Allergy. For women with sulfa allergy, we also modeled first-line treatment with ciprofloxacin instead of tmpsmx. Results using ciprofloxacin were similar to those obtained with tmp-smx, but strategies employing ciprofloxacin were about 10% more expensive than similar strategies using tmp-smx. Pelvic exam and urine cultures for women with negative urinalyses had a marginal costeffectiveness of under $2 per SDA under almost all circumstances. Urine cultures for patients with pyuria were less cost-effective in this population because resistance to ciprofloxacin is still relatively rare.
Cost Considerations. Our base case analysis used conservative cost estimates derived from the Medicare fee schedule 75 and average wholesale prices for drugs. Substituting costs from the physicians' fee reference 76 and neighborhood pharmacy charges did not change the order of the strategies, but did increase the marginal cost-effectiveness per SDA by as much as 10-fold for some strategies. 
DISCUSSION
Despite the publication of numerous guidelines and analyses over the past 25 years, there is still no consensus on the optimal management of dysuria. 20, 77 Previous decision models and analyses have limited themselves to the assessment of a single test. 3, 4, 11, 15 We found, however, that the value of any test depends on its context in the larger management strategy. For example, the cost-effectiveness of urine culture depends on whether it is performed on all women or only those with normal urinalyses, whether pelvic exam is performed, whether the patient receives empiric antibiotics while awaiting culture results, and whether STD cultures are also performed. Our model also offers some general insights about individual tests, but only within the context of the preferred diagnostic strategies. Moreover, we examined the effects of local factors, such as prevalence of sexually transmitted diseases, antibiotic resistance, and patient preferences regarding pelvic examination, which previous studies did not address, but which may justify some of the variation observed in individual practice.
General Insights
Urinalysis Versus Empiric Treatment. In general, if a disease is sufficiently common and therapy is both benign and beneficial, it may be better to treat empirically than to test. 78 In our model, the prevalence of cystitis in every population is high enough, the sensitivity of urinalysis low enough, and the therapy beneficial enough that empiric antibiotics is preferred to urinalysis alone, as others have pointed out. 11, 15, 19 Nevertheless, most experts recommend urinalysis. 1, 5, 10, 26 Our analysis supports this recommendation, not for ruling out disease, but for deciding who needs more testing. Specifically, a negative urinalysis identifies patients likely to benefit from pelvic examination, which is too expensive and uncomfortable to perform on all patients (≥$180 per SDA, depending on the patient's aversion to the exam). Reserving pelvic exam for those with normal urinalyses is much more cost-effective (<$4 per SDA). Only when the probability of cystitis exceeds 85% does the marginal cost-effectiveness of urinalysis exceed $40 per SDA.
Pelvic Exam. Although most experts recommend pelvic examination for patients without pyuria, 1,5,10 many clinicians do not perform it. Their reluctance may stem from perceived patient preferences, clinician discomfort, time constraints, or the knowledge that pelvic disease is rare in a particular population. Unfortunately, apart from vaginal symptoms, history alone has little diagnostic value in the assessment of dysuria, 19 as being young and sexually active are risk factors for both chlamydia and cystitis. Studies have consistently demonstrated that despite good history taking, approximately one-third of women presenting with dysuria do not have cystitis. 11,34,36 -43 In a family practice setting, with more lenient entry criteria, the percentage was much greater. 45 Our results suggest that pelvic examination is the most beneficial test for women with negative urinalyses, even when patients are averse to the exam. Routinely performing STD cultures will generally be quite expensive, but may be appropriate in certain high-risk populations.
Urine Culture. Routine urine culture has been assailed as costly and unnecessary for several reasons. First, most patients with cystitis will be cured before culture results are available. 1 Second, clinicians relying on the traditional definition of 100,000 colonies to diagnose cystitis will fail to diagnose patients with low-count bacteriuria. 44 Finally, in those cases where cultures demonstrate in vitro resistance to the prescribed antibiotic, they do not always predict in vivo response. 79, 80 As an alternative, some experts have advised reserving initial cultures for women without pyuria or bacteriuria. 10, 17 Previous analyses, which concluded that urine culture was not cost-effective, did not consider this option. 3, 4 Our model found that urinalysis-guided culture actually saves money by providing timely diagnosis in cases when empiric antibiotics fail. Routine culture may also be reasonable when antibiotic resistance is common.
Creating a Locally Applicable Algorithm
The appropriate diagnostic work-up depends on local factors, including how much one is willing to pay to avoid a day of dysuria. With unlimited resources, all tests should be performed on all patients, because that results in the fewest symptom-days, even allowing for patient aversion to pelvic examination. On the other hand, if resources were scarce, empiric antibiotics provide substantial benefit at a low cost. When balancing quality and cost, clinicians make this calculation implicitly, while decision analysis makes it explicitly. Moreover, in a complicated decision such as the approach to dysuria, the subtle interaction of multiple tests makes it difficult for anyone to intuit the costeffectiveness of a given strategy. Modeling allows us to examine those interactions and to custom tailor an algorithm to local conditions such as antibiotic resistance, prevalence of disease, and patient preferences, given a value for a day of dysuria avoided. Without making such a value explicit, it is impossible to decide which tests are too expensive to do routinely.
We intentionally did not assign a value to a day of dysuria, because we doubt that there is a single correct value for all patients and all settings. In an informal poll, we found that physicians would pay between $20 and $100 to avoid a day of dysuria, which would produce a range of preferred strategies. For example, if we assume a societal willingness to pay $50,000/quality adjusted life year and a utility for dysuria of 0.71 from the Index of Well Being, office. We estimate that such a woman has a two-thirds chance of having cystitis. If a day of dysuria is not worth even $4 (the marginal cost-effectiveness of urinalysis and pelvic examination) or the clinician believes the patient has an 85% chance of cystitis (as in patients with dysuria, gross hematuria, and no vaginal symptoms), 19 then empiric tmp-smx should be prescribed. Otherwise, urinalysis should be performed. Patients with pyuria or bacteriuria should receive tmp-smx without urine culture, unless local resistance exceeds 40%. Women without pyuria or bacteriuria should have a pelvic examination. If vaginitis or herpes is present, it should be treated appropriately; otherwise, the patient should have a urine culture and be treated with tmp-smx.
Applying the model to a university health service would produce an almost identical algorithm. Empiric antibiotics would be preferred up to a value of $8 for a day of dysuria. Urine culture for pyuria would not make sense even at 40% resistance to tmp-smx. In a family practice environment, however, the algorithm might look very different, especially if patients with some vaginal symptoms are included (Fig. 3b) . Empiric antibiotic therapy is never preferred. All patients begin with pelvic examination, unless a day of dysuria is worth < $33, in which case all patients begin with urinalysis. Patients with pyuria never have a urine culture, regardless of antibiotic resistance.
The model thus demonstrates the importance of collecting local clinical information. In order to successfully craft local guidelines, it is necessary to have data about the clinical setting and its prevalence of disease (walk-in clinic vs family practice vs university health service), antibiotic resistance patterns, and how much it is reasonable to spend to prevent 1 day of dysuria. In the future, any doctor or clinic could generate a locally tailored algorithm by entering such data into our model, perhaps via the internet. 
